Discontinuing Specific Meds Linked to MS Relapse Risk Discontinuing Specific Meds Linked to MS Relapse Risk
In older patients with nonactive MS, there is a significant increased risk for relapse after discontinuing natalizumab and fingolimod, new research showed.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 28, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
Alzheimer's Vaccines Are Back; Streamlining Prior Authorization; Rare APOE Variant
(MedPage Today) -- Interest in vaccines to treat Alzheimer's disease is back, according to interviews with 10 scientists and company executives. (Reuters)
Personalized extended interval dosing using natalizumab (Tysabri) trough levels appeared... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - November 21, 2023 Category: Neurology Source Type: news
Stocks making the biggest moves midday: Warner Bros., Occidental Petroleum, Rivian, Toast and more
Check out the companies making headlines in midday trading. Upstart Holdings — Stock in the artificial intelligence lending platform tumbled more than 27% after missing third-quarter sales and earnings estimates. The company reported an adjusted loss of 5 cents per share on $134.5 million in…#upstartholdings #tysabri #leqembi #reatapharmaceuticals #occidentalpetroleum #houston #refinitiv #rivian #toast #boston (Source: Reuters: Health)
Source: Reuters: Health - November 8, 2023 Category: Consumer Health News Source Type: news
Novartis' knockoff of Biogen's Tysabri is first MS biosim in US
Two months after a federal court in Delaware rejected Biogen’s patent infringement c | The FDA has endorsed Novartis' Tyruco as the first U.S. biosimilar to treat multiple sclerosis. The copycat will compete with Biogen's Tysabri, covering all of the original drug's indications for relapsing MS in…#delaware #biogen #fda #novartis #tysabri #crohn (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2023 Category: Consumer Health News Source Type: news
First Biosimilar, Tyruko, Approved to Treat Multiple Sclerosis
FRIDAY, Aug. 25, 2023 -- The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announced... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 25, 2023 Category: General Medicine Source Type: news
FDA Okays First Biosimilar for Multiple Sclerosis FDA Okays First Biosimilar for Multiple Sclerosis
Sandoz ' s natalizumab-sztn injection (Tyruko) is on par with Biogen ' s Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 25, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
First Multiple Sclerosis Biosimilar Approved
(MedPage Today) -- The first biosimilar for multiple sclerosis (MS) was approved, the FDA announced late Thursday.
Natalizumab-sztn (Tyruko) was approved as a biosimilar to natalizumab (Tysabri) injection to treat clinically isolated syndrome... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 25, 2023 Category: Gastroenterology Source Type: news
FDA Approves Tyruko (natalizumab-sztn), a Biosimilar to Tysabri
August 24, 2023 -- The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS). Tyruko, like... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 24, 2023 Category: Drugs & Pharmacology Source Type: news
FDA Approves First Biosimilar to Treat Multiple Sclerosis
FDA has approved the first biosimilar to Tysabri (natalizumab) injection for the treatment of relapsing forms of multiple sclerosis. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 24, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Biogen to bulk up rare disease treatments with $7 billion Reata acquisition
Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The Alzheimer’s treatment developer said Friday it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year. Plano, Texas-based Reata focuses…#biogen #reatapharmaceuticals #reata #plano #fda #freidreich #techfidera #tysabri #spinraza #leqembi (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2023 Category: Consumer Health News Source Type: news
Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable
stock fell Tuesday after the company said it plans to cut about 1,000 jobs in an effort to cut operating expenses. The announcement came as Biogen reported better-than-expected second-quarter financials, as earnings fell more than 20% with its fully approved Alzheimer's drug, Leqembi, not yet…#biogen #leqembi #cambridge #chrisviehbacher #tecfidera #vumerity #plegridy #tysabri #centersformedicare #medicaidservices (Source: Reuters: Health)
Source: Reuters: Health - July 25, 2023 Category: Consumer Health News Source Type: news
Stem Cell Transplant More Effective Than Some MS Therapies Stem Cell Transplant More Effective Than Some MS Therapies
Autologous stem cell transplant reduced the risk for relapses, compared with fingolimod and natalizumab, in a recent analysis.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 31, 2023 Category: Neurology Tags: Hematology-Oncology News Source Type: news
Prion Disease in Human Tears; Functional vs Primary Tics; COVID-19 and the Brain
(MedPage Today) -- Misfolded prion protein was detectable in tear fluid of people with Creutzfeldt-Jakob disease. (New England Journal of Medicine)
Autologous hematopoietic stem cell transplants showed benefit over fingolimod (Gilenya) and natalizumab... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 16, 2023 Category: Neurology Source Type: news
Biosimilar Equal to Natalizumab for Relapsing-Remitting MS Biosimilar Equal to Natalizumab for Relapsing-Remitting MS
A novel biosimilar matches natalizumab in terms of efficacy, safety, and immunogenicity in patients with relapsing remitting multiple sclerosis, results from a new phase 3 trial show.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 27, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
New Evidence Sheds Light on Stem Cell Transplantation for Progressive MS
(MedPage Today) -- Autologous hematopoietic stem cell transplantation (AHSCT) was not superior in preventing relapses or reducing disability progression than natalizumab (Tysabri) in progressive multiple sclerosis (MS), new research suggested... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 31, 2022 Category: Neurology Source Type: news
